MedTrace Logo

Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus

NCT03562975 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2024-12-10

Study results available
· View outcomes & findings →

Summary

The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.

Conditions

Interventions

DRUG

Ocrelizumab

Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • University of South Florida

    lead OTHER

Principal Investigators

  • Janice Y Maldonado, MD · University of South Florida

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-23
Primary Completion
2023-01-11
Completion
2023-01-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03562975 on ClinicalTrials.gov